erlotinib

EGFR tyrosine kinase inhibitors, including osimertinib, generally exhibit lower efficacy in patients with the L858R-mutant NSCLC compared with those with exon 19 deletion (del19). Grade more than or equal to 3 adverse events occurred in 42% of patients. In real-world settings, RAM plus ERL demonstrated favorable efficacy in patients with L858R-mutant NSCLC and manageable toxicity.

Targeting HIF-1α disrupts metabolic reprogramming and hypoxia adaptation, thereby enhancing erlotinib efficacy. This combined approach highlights the therapeutic potential of HIF-1α inhibition as a novel strategy to overcome EGFR-TKI resistance in NSCLC.

P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Molecular docking revealed higher binding affinities for both Idarubicin (- 9.98 kcal/mol) and Larotrectinib (- 9.42 kcal/mol) compared to the reference drug Erlotinib (-8.91 kcal/mol). Additionally, they demonstrated favorable predicted cytotoxicity against NSCLC cell lines. In conclusion, our integrated bioinformatics analysis identifies idarubicin and larotrectinib as putative candidates for drug repurposing targeting EGFR in NSCLC, providing a rational foundation for future experimental validation and further preclinical and clinical investigations.

There are a number of systemic and ocular side effects associated with erlotinib. Ocular adverse effects such as dry eye, epithelial keratopathy, nonhealing corneal epithelial defects, corneal ulceration, conjunctivitis, anterior uveitis, trichomegaly, and periorbital skin rash leading to ectropion and epiphora have been reported in the literature. To our knowledge, this is the first reported case of conjunctival ulceration associated with the use of erlotinib.

A virtual cohort of 1,000 patients with advanced EGFR-mutant NSCLC received osimertinib (80 mg daily) or comparator first-line EGFR-tyrosine kinase inhibitors (gefitinib/erlotinib). Probabilistic analyses confirmed PMX superiority across willingness-to-pay thresholds. Pharmacometric models, enabling individualized dosing and exposure-driven effects, provide more biologically plausible estimates, supporting their integration into HTAs for precision oncology.

Of 52 patients (55.8% female; mean age 64.5 years), 59.6% received chemotherapy and 40.4% received an EGFR TKI as first-line treatment; erlotinib constituted 71.2% of targeted therapies. These results suggest that HER3 expression may warrant further investigation as a candidate biomarker for treatment sequencing decisions and as a potential therapeutic target in EGFR-mutant NSCLC. Prospective studies evaluating chemotherapy-TKI sequencing and HER3-directed agents such as patritumab deruxtecan (HER3-DXd) in HER3-positive patients are needed to confirm these preliminary observations.

Key derivatives demonstrated superior predicted binding affinity and complex stability compared to the reference inhibitor erlotinib...Collectively, this work validates the 1,2,4-oxadiazole core as a promising scaffold for dual HER2/ERα inhibition and provides a rational, multi-faceted computational blueprint. The identified lead compounds warrant subsequent experimental validation, and the established framework serves as a valuable template for accelerating the discovery of next-generation targeted cancer therapies.

EGFR-focused TKIs were largely disappointing as a treatment for GBM. Longstanding issues, including treatment resistance, tumor heterogeneity, and blood-brain barrier penetration persist. Future efforts must focus on tackling these issues, and prioritizing patient selection via biomarkers.

Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population.

A focused translational approach that combines structural insights with innovative therapeutic strategies is urgently needed to achieve lasting clinical benefits in EGFR-driven cancers.

P1, N=55, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027